Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with SOX and Radiotherapy for EGJ Adenocarcinoma
NCT06250894Phase 2Recruiting
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in esophagogastric junction adenocarcinoma (GEJA). Started Mar 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT06250894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250894.